New documents expose flaws in Medicare’s rushed AI prior-authorization pilot

New internal documents have highlighted serious shortcomings in Medicare’s recently launched AI-driven prior‑authorization pilot, which was rolled out faster than anticipated.

The pilot, designed to automate and speed up prior‑authorization decisions, appears to suffer from insufficient testing, unclear implementation guidelines, and operational glitches that could delay patient access to treatments.

These revelations are prompting policymakers to reconsider the rollout strategy and may influence how Medicare and other payers adopt AI tools, a development that could affect pharmaceutical companies that rely on prior‑authorization processes for their products.